Skip to main content
. Author manuscript; available in PMC: 2010 Jul 9.
Published in final edited form as: Oncol Rep. 2010 Jul;24(1):15–24. doi: 10.3892/or_00000823

Figure 4.

Figure 4

Western blot analysis of SSAT (A) and SMO (B). A2780 cells were treated with Pd-spermine, Pt-spermine or cisplatin/DENSPM, all at 10 μM concentration each for 20 h followed by 24 h incubation in drug free medium. The cells were harvested thereafter and 60-80 μg of whole cell extracts were used for Western blot and probed with human SSAT antibody (A) or SMO antibody (B). Untreated cells were used as control for both. NIH3T3 cells treated with DENSPM were used as a positive control for SSAT (A) and HCT-116 cells treated with oxaliplatin/DENSPM were used as a positive control for SMO (B). A2780 cells treated with oxaliplain/DENSPM were also used as a positive control for SSAT and SMO. Note that fold changes could not be presented in 4A, as controls had no measurable SSAT protein.